Antihistone Autoantibodies in Dobermans With Hepatitis by Dyggve, H. et al.
Antihistone Autoantibodies in Dobermans With Hepatitis
H. Dyggve , S. Meri, T. Spillmann, H. Jarva, and M. Speeti
Background: Immune system involvement is suggested as an underlying cause for Doberman hepatitis (DH) based on
female predisposition, lymphocyte infiltration, abnormal hepatocyte expression of major histocompatibility complex class II
antigens, and homozygosity for dog leukocyte antigen DRB1*00601.
Objective: To measure serum antinuclear antibodies (ANA) and serum antihistone antibodies (AHA) in Dobermans with
hepatitis. To determine whether increased serum ANA or serum AHA could be used to support the diagnosis of Doberman
hepatitis (DH).
Animals: Privately owned 25 subclinically and 13 clinically affected DH Dobermans and 17 healthy control Dobermans.
Methods: Case–control study. Indirect immunofluorescence (IIF) microscopy and line blot tests were employed for the
ANA pilot studies and an enzyme-linked immunosorbent assay (ELISA) assay for detection of IgG AHA.
Results: Indirect immunofluorescence revealed ANA-positive cases, and line blot showed AHA reactivity. In ELISA,
importantly increased concentrations of AHA were found in 92% (23/25) of dogs in the subclinical stage and 84.6% (11 of
13) of dogs in the clinical stage of DH compared with no control dogs (0/17) (P < 0.0005). The mean AHA absorbance val-
ues of the blood samples obtained from the 25 subclinical DH dogs (1.36  0.60, mean  SD) and the 13 clinically affected
dogs (1.46  0.49) were significantly higher than in 17 control dogs (0.51  0.18; P < 0.0001).
Conclusions and Clinical Importance: As the presence of AHA indicates autoimmune activity, our results favor an autoim-
mune background as one cause for DH. Antihistone antibody could represent a novel means for screening Dobermans with
increased serum alanine transaminase concentrations and suspicion of DH.
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Hepatitis in Dobermans is a rare chronic liver dis-ease of unknown etiology. It typically affects
females and is characterized by increased alanine
transaminase (ALT) activity, progressive lymphocyte-
predominant inflammation, and increased hepatic copper
content that correlates with parenchymal inflamma-
tion.1,2 Two competing models for Doberman hepatitis
(DH) etiology have been proposed. One suggests that
DH is a form of copper toxicosis, as Dobermans with
hepatitis have had increased copper concentrations in the
liver.3 According to the second theory, DH is due to a T-
cell–mediated autoimmune response in genetically predis-
posed individuals.4 Involvement of the immune system is
suggested by female predisposition, the presence of lym-
phocyte infiltration, an abnormal expression of major
histocompatibility complex (MHC) class II antigens by
the hepatocytes,4 and homozygosity for the risk allele
DRB1*00601 of the dog leukocyte antigen (DLA)
system.5 In early DH, the most prominent feature is
mononuclear cell infiltration in the parenchymal and por-
tal areas of the liver. As the disease gradually progresses,
further structural changes develop, and the histology has
more characteristic features of the human leukocyte anti-
gen (HLA)-associated autoimmune hepatitis (AIH), with
more typical interface hepatitis and bridging necrosis
changes.2,6 The risk of developing DH is hereditary, and
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it seems to be a complex trait disease, a condition in
which the mode of inheritance involves one or more
genes that operate alone or together, in combination with
environmental factors.5
Autoantibodies are one of the characteristics of
autoimmunity. In humans, autoantibodies are screened
to diagnose an autoimmune disorder and, in some
cases, to monitor disease progression.7 While most
autoantibodies are not known to be pathogenic, many
are linked to the development of autoimmune diseases.
Therefore, autoantibodies play a substantial role in the
study of autoimmune disease processes.8 In general, the
immune system has a remarkable capacity to prevent
self-antigens from stimulating autoimmune reactivity.
Autoreactive B cells are efficiently removed at 2 check-
points to ensure self-tolerance. The first checkpoint
occurs in the bone marrow, where many autoreactive B
cells undergo clonal deletion or become anergic as they
mature.9 The second checkpoint is situated in the
periphery, where the mechanisms are thought to be
based largely on defective activation signals given to the
lymphocyte when it encounters a self-antigen. This phe-
nomenon leads to a state of anergy or apoptosis.9
Defects in the first and second checkpoints have been
observed in human patients with rheumatoid arthritis
(RA)10 and systemic lupus erythematosus (SLE).11 High
levels of antihistone antibodies (AHA) have been
described in different autoimmune conditions of
humans, such as in primary biliary cholangitis (PBC),12
induced or spontaneous SLE,13 type 1 autoimmune hep-
atitis (AIH-1),14,15 and RA.16
Our previous findings suggest that DH is a tissue-
specific autoimmune disease.2,5 To test the hypothesis
that Dobermans with DH have autoantibodies, a case–
control study was performed. Also, we addressed the
question of whether these antibodies could be used for
supporting in the diagnosis of the disorder.
Materials and Methods
Study Material
The study material consisted of 25 subclinical DH Dobermans
(SDH) (20 females and 5 males) and 13 Dobermans suffering from
clinical Doberman hepatitis (CDH) (11 females and 2 males). A
suspicion of DH was raised when a Doberman had a >3-fold ele-
vation in serum ALT values (reference limit 18–77 U/L). The
mean ALT concentration in the SDH group was 759 U/L (range,
256–1,575 U/L) and in the CDH group 837 U/L (range, 496–
1,157 U/L). DH was diagnosed histologically in both groups by a
liver biopsy with hematoxylin and eosin staining, demonstrating
mononuclear cell infiltration in the parenchymal and portal areas
of the liver and distinct degree of fibrosis and necrosis. In the
SDH group, 6 dogs had slight fibrosis, and of these dogs, mild
bridging necrosis was found in 5 dogs and 1 dog had multifocal
apoptotic cells. Clinical Doberman hepatitis dogs showed moder-
ate-to-marked fibrosis and moderate-to-massive necrosis. The
CDH dogs were biopsied postmortem. The rubeanic acid stains
were positive for copper in all DH dogs, based on granular cyto-
plasmic staining in the hepatocytes. The degree of copper accumu-
lation was evaluated on a scale 0–5 with a previously characterized
classification.17 In the SDH group, 3 dogs were grade 1, 3 were
grade 1–2, 9 were grade 2, 6 were grade 2–3, and 4 were grade 3.
In the CDH group, 3 were grade 1, 8 were grade 2–3, 1 was grade
3, and 1 was grade 4. In the SDH dogs, the copper was associated
with inflammation focally in the centrilobular region. The copper
was mainly associated with inflammation in the periportal and
bridging necrosis areas in the CDH dogs. Quantitative copper was
performed for 11 SDH dogs with a median of 792 lg/g dwl (dry
weight liver) (range 430–1,886 lg/g dwl) and 7 CDH dogs with a
median of 1,490 lg/g dwl (range 630–2,430 lg/g dwl). The median
age at diagnosis in the SDH group was 4.9 years (range, 1.9–
8.6 years). In the CDH group, the age distribution was 2.5–
10.3 years, with a median age of 6.2 years at diagnosis.
The control group comprised 17 apparently healthy Dobermans
(10 females and 7 males). The health status of the control dogs
was evaluated based on history (no clinical signs of liver or other
systemic disease), a complete physical examination, and hematol-
ogy, full chemistry profile, and urinalysis. All dogs had normal
ALT values. These dogs were examined at the University Small
Animal Hospital, Faculty of Veterinary Medicine, University of
Helsinki, Finland. Four control dogs were biopsied, and no hep-
atic changes were revealed in the histological analysis. The age dis-
tribution of the controls was 2.7–13 years, with a median age of
8.2 years.
The study was approved by the National Ethics Committee for
Animal Experiments in Finland (ESLH200908997/Ym23). All
dogs were privately owned Finnish Dobermans, and the owners
provided written consent for participation. The samples were gath-
ered during 1981–2010 and stored at 20°C. For the assays, the
samples were thawed and analyzed on the same day. None of the
dogs received immunosuppressive medication.
Methods
An indirect immunofluorescence (IIF) test was carried out to
screen for possible autoantibodies in sera. This test was followed
by a line immunoassay (INNO-LIA antinuclear antibody [ANA]
Update) for detecting different antinuclear antibodies in a smaller
number of cases and controls, as described below. Finally, we per-
formed an enzyme-linked immunosorbent assay (ELISA) for AHA
on all cases and controls.
Determination of Autoantibodies by IIF
The presence of antibodies in the sera was analyzed by IIF on
mouse liver cryostat sections. We collected serum samples from 8
SDH (7 females and 1 male) and 2 CDH (1 female and 1 male)
dogs in the case group and 10 healthy control Dobermans (6
females and 4 males). These samples were diluted to 1 : 10, 1 : 40,
and 1 : 160 in 1% BSA/PBS (w/v; 0.5 g bovine serum albumin
and 50 mL of phosphate-buffered saline, pH 7.4). Thirty micro-
liters of the diluted sera was applied to the sections and incubated
for 30 minute at room temperature (RT). The liver sections were
then rinsed with PBS. The primary rabbit anti-dog IgG antibodya
was diluted at 1 : 200 in BSA/PBS, and the sample slides were
incubated for 30 minute at RT. The sections were then washed
with PBS and treated with Alexa-fluor 488 donkey anti-rabbit
IgGb at 1 : 400 dilution for another 20 minute at RT. After incu-
bation, the slides were again washed with PBS. All incubations
were made in a humid chamber to prevent excess drying. The
stained samples were then examined under an Olympus
fluorescence microscope. (Olympus, Hamburg, Germany).
Line Blot Analysis of Antinuclear Autoantibodies
To detect the presence of antibodies against nuclear and cyto-
plasmic autoantigens, a commercial INNO-LIA ANA Update testc
was used. The test can detect antibodies against 13 different
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nuclear and cytoplasmic antigens in human sera. In this assay,
recombinant antigens (SmB, RNP-70k, RNP-A, RNP-C,
SSA/Ro52, SSB/La, Cenp-B, Topo-1/Scl-70, Jo-1), synthetic pep-
tides (SmD and ribosomal P antigen), and natural proteins (SSA/
Ro60 and histones) are attached to separate lines on a membrane.
In addition to the autoantigens, 1 control line is present on each
strip. We employed the test for antibodies in dogs as previously
described18 and used the diluents, buffers, and color developers
provided by the manufacturer. Nine SDH (7 females and 2 males)
and 1 female CDH Doberman were included in the case group
and 10 healthy Dobermans (6 females and 4 males) in the control
group. The serum specimens were diluted 1 : 200, and the strips
were then incubated in diluted serum for 1 hour at RT. After this,
the blots were washed and incubated with a 1 : 2,000 diluted pri-
mary rabbit antidog poly-Ig antibody for 1 hour at RT. After the
second wash, the secondary antibody (anti-rabbit) labeled with
alkaline phosphatase and diluted to 1 : 2,000 was added for
1 hour at RT. After the last wash, a color substrate was added for
antibody detection and left for 1 hour at RT. The color reaction
was then stopped with the provided sulfuric acid. The bands were
detected by visual interpretation by the same nonblinded examiner.
The control strip was without serum overlay, but was otherwise
handled the same way as the other strips in the assay.
Determination of Antihistone Autoantibody Levels by
ELISA
After reactivity with the histone antigen had been noted in the
line blot, we decided to confirm this finding with a second method.
Therefore, an in-house ELISA assay for the detection of AHA was
set up. Altogether, 38 sera from DH cases and 17 sera from healthy
controls were analyzed. A calf thymus histone preparationd was dis-
solved in carbonate buffer (pH 9.6) at a concentration of 1 lg/mL
and coated onto Maxisorp microtiter platese overnight at +4°C. The
plate was next washed 5 times with 0.05% Tween 20/PBS (PBS/
Tween). Serum overlay in duplicate (dilution at 1 : 600 in PBS) was
incubated on the plates for 1 hour at RT, and then the wells were
washed 5 times with PBS/Tween. Rabbit antidog IgG was used as
the primary antibody in 1 : 5,000 dilution in BSA/PBS and incu-
bated for 1 hour at RT. The plates were then washed 5 times with
PBS/Tween. An HRP-conjugated goat anti-rabbit IgG antibodyf
was applied as a secondary antibody for 1 hour at RT in a 1 : 2,000
dilution in BSA/PBS. After 5 PBS/Tween washes, the enzyme
activity was determined by adding 100 lL of 8 mg OPD
(o-phenylenediamine dihydrochlorideg ) diluted in 12 mL milliQ
water and 5 lL H2O2 (30%). The obtained reaction was stopped by
adding 100 lL of 1 M H2SO4. The optical density (OD) was mea-
sured at a wavelength of 492 nm.
One histone-reactive DH sample was chosen as a designated
positive control sample and was analyzed at the same location on
each plate. The obtained results were adjusted toward this sample
for result comparison. The mean absorbance value (the ratio of
the absorbance of the tested sample over the absorbance of the
positive control sample) for healthy control dogs +2 SD (0.87) was
used as a cutoff value for seropositivity. Control sera were stored
in 20°C in aliquots and thawed just before use. All
measurements were repeated twice.
Statistical Analysis
The statistical analyses were performed with a commercially
available statistical program (PASW 18.0 software for Windowsh )
with both Student’s t-test and Fisher’s exact test on each ELISA
sample group. For normally distributed data, the results were
expressed as mean  SD, and differences with P-values < 0.05
were considered significant. The normality assumption was
satisfied by visual interpretation of the Q–Q plots. Graphical data
presentation was performed with GraphPad Prism.i
Results
Indirect Immunofluorescence Detection of Antinuclear
Autoantibodies
The immunofluorescence analysis of DH samples
using mouse liver sections revealed a typical staining for
ANA. In a pilot test of 10 DH cases, 5 serum samples
were positive in the ANA test. Two sera (1 SDH and 1
CDH Doberman) showed an ANA titer of 1 : 40, 2
subclinical dogs had a titer of 1 : 160, and 1 subclinical
dog had a titer of >1 : 160. All ANA-positive cases
showed a homogeneous nuclear pattern (Fig 1). In the
control group, 1 of 10 sera showed a detectable ANA
at a titer of 1 : 10, and the remainder of healthy con-
trols were seronegative.
Line Blot Analysis of Antinuclear Autoantibodies
Four of 10 DH serum samples (3 SDH and 1 CDH
dog) showed clear antihistone reactivity. None of the
tested control dog sera reacted with histones. Anti-
RNP-A was present in 1 SDH and 1 CDH case as well
as in 1 healthy control. Also, 1 subclinical dog had
anti-SmD and another anti-SmB reactivity. Additional
minor reactivity was seen mostly in the case samples.
Positive reactivity was observed toward SSA/Ro60 in
all study samples (Fig 2). The presence of AHA was
also tested by Far-Western blotting with a calf histone
preparation,4 and the results were similar to those of
the ELISA analysis (data not shown).
Enzyme-Linked Immunosorbent Assay Analysis of
Antihistone Antibodies
Overall, samples from 38 DH-positive Dobermans
(25 SDH and 13 CDH) and sera from 17 clinically
healthy control Dobermans were analyzed. The AHA
result was above the cutoff value in 23 of 25 SDH dogs
(92%) and in 11 of 13 CDH dogs (85%). All 17 con-
trols were seronegative. These results showed a signifi-
cant association between AHA IgG and DH
(P < 0.0005). The antibody results showed a greater
variation in the case groups. When comparing the mean
absorbance values, SDH (1.36  0.60, mean  SD) and
CDH (1.46  0.49) absorbance values were both signifi-
cantly higher than the values for controls (0.51  0.18;
P < 0.0001). The difference between the subclinical and
clinical case groups was not significant (P = 0.29)
(Fig 3). One subclinical dog was an outlier with a
higher value, and the statistical tests were carried out
with and without this result. The resulting outcome
remained the same even when the outlier was included
in the analysis.
Thus, in total, 34 of 38 dogs (89%) with either sub-
clinical or clinical disease had IgG AHA at a dilution
of 1 : 600. The ELISA assay had a sensitivity of
89.5% (95% confidence interval [CI] from 75.20 to
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97.06%) and a specificity of 100% (95% CI from
80.49 to 100.00%) for detecting subclinical or clinical
DH.
Discussion
The main goal of this study was to gather evidence
that autoimmunity can be one cause of DH. We were
able to demonstrate significantly increased levels of
AHA in both SDH and CDH Dobermans. Moreover,
the healthy control Dobermans were all seronegative
for AHA measured by line blot analysis and ELISA.
An autoimmune disease is a condition in which tissue
injury is caused by an abnormal T cell or antibody
reaction to self. The modified Witebsky’s postulates19,20
characterize the different types of experimental criteria
A B
C D
Fig 1. Indirect immunofluorescence analysis of autoantibodies at 4009 magnification. The sera were diluted 1 : 10, 1 : 40, and 1 : 160
and incubated on mouse liver slides for detection of antinuclear antibodies. In the case group, 5 of the 10 samples were positive in the
antinuclear antibody (ANA) test. (A) ANA titer of 40 was seen in 2 of the 10 samples (inset at 1,0009 magnification). (B) Two of 10 sam-
ples had an ANA titer of 160. (C) One of the case group samples had a titer of >160. (D) A sample with no detectable ANA, dilution
1 : 10. Scale bar 25 lm. Representative data are shown.
Fig 2. Line blot analysis of antinuclear antibodies in 10 controls (1–10) and 10 DH cases (11–20). Altogether 4 cases (3 of 10 subclinical
and 1 of 10 clinical) showed antihistone reactivity in the line blot. Anti-RNP-A was present in 1 subclinical and 1 clinical case as well as in
1 healthy control. In addition, 1 subclinical dog had anti-SmD, and another had anti-SmB reactivity. All strips, including the negative con-
trol, reacted toward SSA/Ro60. The control strip (Ctrl) was incubated without serum but with buffer, and otherwise handled the same way
as the other strips.
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used to assess whether a disease is of autoimmune ori-
gin. These criteria are divided into direct proof and
indirect and circumstantial evidence. The direct proof
proposes that an autoimmune reaction is reproduced in
a normal recipient by transferring a pathogenic anti-
body. The indirect evidence requires that a similar dis-
ease is reproduced in animals kept under experimental
settings. Many disease processes are described by the
word “autoimmune” even though they neither meet
direct nor indirect criteria but have strong circumstan-
tial evidence for support. Suspicion of an autoimmune
disorder can be raised when affected patients have a sta-
tistical association with a particular MHC class II hap-
lotype, an abnormal expression of MHC class II
proteins on the affected organ, a lymphocytic infiltra-
tion of the target organ, increased levels of autoanti-
bodies, a favorable response to immunosuppression, a
positive family history of the disease, or an association
with another autoimmune disease in the same individual
or their family. Female predisposition is also typical for
many autoimmune diseases.9
Many of these aforementioned circumstantial mecha-
nisms and elements underlying autoimmune responses
have been identified in humans. The most thoroughly
described predisposing genetic factor in the development
of nearly all autoimmune diseases is the MHC class II
association.21 In the development of T-cell tolerance,
these MHC class II molecules present self-antigens on
the surface of professional antigen-presenting cells to
na€ıve T cells. The self-antigen and MHC class II mole-
cule complex guides T cells to survive or perish. In this
way, these genes have a central role in the development
of T-cell tolerance.22 The expression of MHC proteins
can also be induced in endothelial cells by inflammatory
conditions in the target organs of autoimmune diseases.
An abnormal hepatocyte expression of MHC class II is
seen, for example, in the cholestatic autoimmune dis-
eases PBC and chronic sclerosing cholangitis.23,24 It has
been proposed that autoimmune diseases have common
genetic factors predisposing to autoimmunity, as a
familial clustering of the same autoimmune illness or
occurrence of multiple autoimmune diseases in the same
individual or the family is recognized.25 Patients with
AIH may have associated autoimmune features or a
family history of other autoimmune diseases such as
autoimmune thyroiditis,26 inflammatory bowel disease,
type 1 diabetes, and arthritis.27 Except for diabetes mel-
litus, human autoimmune diseases are more common in
females, but the reasons for this sex bias remain mostly
unknown. X-chromosomal and hormonal factors, or
lack of protective Y-chromosomal factors, have been
suggested to play a role.28
The typical histological characteristics of human AIH
include interface hepatitis with portal and periportal
monocellular infiltrates, and, usually, clusters of plasma
cells. Fibrosis is featured in all but the mildest variants
of the disease.6 An important part of the diagnostic
process is the detection of autoantibodies in patients
with suspected autoimmune disease. People with AIH
have increased levels of autoantibodies that can be used
to diagnose and differentiate the condition from other
forms of chronic hepatitis. Autoimmune hepatitis can
be further subclassified as AIH-1 and AIH-2 according
to different antibody patterns. The standard antibody
pattern for the diagnosis and classification of AIH-1
requires the identification of ANA,29 smooth muscle
antibodies,30 and antibodies to soluble liver antigen
(SLA).31 Anti-SLA is detected in 15–30% of AIH-1
patients and is associated with a more severe disease
course. Thus, anti-SLA antibodies can be of prognostic
value.32 The more serious form of AIH, AIH-2, is usu-
ally characterized by antibodies against liver-kidney
microsome type 1 (anti-LKM1).33 Antibodies to his-
tones, although not pathognomonic, are present in 35%
of ANA-positive patients with AIH.14
A suspicion for an immune-mediated background for
DH was raised based on similar characteristics to autoim-
mune diseases in humans. The Doberman breed is at
increased risk of the development of a severe form of
chronic hepatitis and cirrhosis, and affected dogs exist in
the same litter and lines of descent.1,34 Hepatitis in
Dobermans mainly affects females.1,35 An association of
many different DLA class II alleles and haplotypes with
immune-mediated diseases in disease susceptibility has
been previously established in dogs. In DH, homozygos-
ity for the DLA allele DRB1*00601 of the DLA system
genotype was significantly associated as a risk factor for
DH.5 In early DH, the most prominent feature in histol-
ogy is mononuclear cell inflammation in the parenchymal
and portal areas of the liver. Also, an aberrant expression
of MHC class II antigens on hepatocytes that correlated
with the degree of inflammation was noted.4
Our aim was to investigate the presence of autoanti-
bodies in DH and to find more proof for the suspected
autoimmune background. Two studies have previously
reported autoantibodies in DH. One study assessed the
presence of circulating autoantibodies with IIF in 3 DH
Dobermans.36 One DH dog had been ANA-positive at
a titer 1 : 10 with a granular nuclear fluorescent
staining. However, antiliver membrane antibodies (anti-
Fig 3. Enzyme-linked immunosorbent assay results for IgG anti-
bodies against histone comparing DH patients with control dogs
in 1 of 600 dilution. A cutoff value of 0.87 for positivity is indi-
cated with a dotted line. Subclinical DH cases (n = 25,
mean  SD: 1.36  0.6) and clinical DH cases (n = 13,
1.46  0.49) were both significantly higher than values for controls
(n = 17, 0.5  0.18; P < 0.0001). A statistical difference was not
noted between the case groups (P = 0.29).
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LMP), smooth muscle antibodies, and antimitochon-
drial antibodies (AMA) were not present. No details
concerning these dogs0 medical records were given.36
The other study found anti-LMP in connection with
chronic hepatitis in a study on 21 canine patients of dif-
ferent breeds, including 4 Dobermans. Two of the
Dobermans had high anti-LMP titers, while the other 2
were anti-LMP-negative. The latter 2 were on corticos-
teroid treatment.37
Previous work in dogs has reported AHA to be com-
mon in dogs suffering from SLE.38 Besides having a
nuclear function, recent studies have indicated a signifi-
cant toxic or pro-inflammatory effect of histones when
released into extracellular space by damaged and acti-
vated cells.39 Histone release has been suggested to play
a part in autoimmune disease,40 not just acting as a
direct autoantigen, but also magnifying the destructive
autoimmune processes.41
In the present study, significantly increased levels of
AHA in both SDH and CDH Dobermans were detected.
This result provides supporting evidence for the earlier
suggestion that the immune tolerance has failed in DH, a
key feature seen in autoimmune disorders. Furthermore,
we wanted to determine whether these antibodies could
aid the disease diagnostics. Based on our results, an
increased AHA titer in conjunction with a high ALT con-
centration in a Doberman with or without clinical signs
of hepatitis supports the diagnosis of DH. A negative
AHA result does not completely rule out DH. The differ-
ence between the 2 case groups SDH and CDH was not
statistically significant (Fig 3), suggesting that AHA is
not a suitable biomarker for disease progression. The
gold standard for diagnosing DH is histopathological
evaluation of liver tissue for typical histopathological
findings and to analyze the copper content. Antihistone
antibody screening could be a valuable tool in DH diag-
nostics in the subclinical and especially in the clinical
stage of DH, if taking a liver biopsy is not performed due
to potential significant risk of bleeding or due to client
concerns or constraints. In this case, an aspirate and
cytology could be considered to attempt to detect hepatic
copper.42
Anti-RNP-A was found in 1 SDH and 1 CDH case
as well as in 1 healthy control. This reactivity does not
fulfill the criteria for RNP autoantibodies. Nonspecific
positive reactivity was observed toward SSA/Ro60
(Fig 2) in the line blot analysis, and, apparently, this
was due to the reactivity of the secondary antibody.
The differences in the female/male ratio between the
DH and control groups may have had an influence on
the data. This is, however, unlikely due to the result
that also males were positive among the SDH and
CDH dogs. A limitation of our study was that there
was not enough serum for some cases to make all the
different assays and the World Small Animal Veterinary
Association’s (WSAVA) standardized evaluation of
histopathology could not be performed for all the older
DH samples. The grading of histopathological findings
for chronic hepatitis was based on Knodell’s
method.2,43 Also, the histopathological evaluation was
not available for all of the control dogs. Nonetheless,
these dogs were considered healthy at the sampling, and
their health status was followed until 2 years after sam-
pling with no elevation of ALT. One limitation was that
copper was not quantified in all DH dogs; however it
was scored and found in association with inflammation
in DH dogs.
Conclusions and Prospects
Our findings provide novel information about dogs
suffering from DH. To date, the etiology and pathogenic
mechanisms of DH remain unknown. Our autoantibody
findings, combined with previous observations in DH,
support the theory that DH has an autoimmune origin.
From a clinical standpoint, AHA may be a useful bio-
marker that could be used to improve the currently diffi-
cult early diagnosis of DH in Dobermans with increased
ALT concentrations. Further studies are needed to reveal
the link between autoimmunity, liver damage, and abnor-
mal copper retention in DH.
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